Document Detail


Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction.
MedLine Citation:
PMID:  11929349     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To compare the costs to the Spanish healthcare system of 35 days' treatment with triflusal (600 mg/day) and aspirin (300 mg/day) in patients with confirmed acute myocardial infarction within 24 hours of onset of symptoms. DESIGN: A cost minimisation analysis based on the results of the Triflusal in Acute Myocardial Infarction study (TIM) was conducted. The hypothesis was that despite a higher acquisition cost of triflusal, savings would result because of differences in efficacy and safety outcome (non-fatal cerebrovascular event and haemorrhagic events). Diagnostic Related Groups were used as a proxy for determining hospital costs in Spain and the values were obtained from different sources and refer to year 2000 costs. Only direct medical costs were considered for the economic analysis. RESULTS: Although the acquisition cost of triflusal was more expensive than that of aspirin, the cost of prevented events - non-fatal ischaemic cerebrovascular events and cerebral haemorrhages - entirely compensated for the cost of triflusal. The overall cost of treating patients with triflusal, compared with aspirin, represented a net saving of 28.4% per patient treated. CONCLUSION: Our study showed that triflusal is cost saving compared with aspirin in the treatment of the acute phase of myocardial infarction.
Authors:
Josep Darbà; Iñaki Izquierdo; Caridad Pontes; Carlos Navas; Joan Rovira
Related Documents :
14976449 - Gabexate mesilate and heparin responsiveness in coronary patients.
16401379 - Appropriate invasive and conservative treatment approaches for patients with st-elevati...
10101569 - A case report of heparin resistance due to acquired antithrombin iii deficiency.
8641009 - Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-...
19528339 - Triple versus dual antiplatelet therapy in patients with acute st-segment elevation myo...
15448779 - Treating heparin-induced thrombocytopenia. the unconventional way!
22848809 - Comparative analysis between spect myocardial perfusion imaging and ct coronary angiogr...
7738749 - Left ventricular failure complicating severe pediatric burn injuries.
9581609 - Influence of aging or left ventricular hypertrophy on the human heart: contents of phos...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  PharmacoEconomics     Volume:  20     ISSN:  1170-7690     ISO Abbreviation:  Pharmacoeconomics     Publication Date:  2002  
Date Detail:
Created Date:  2002-04-03     Completed Date:  2002-06-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9212404     Medline TA:  Pharmacoeconomics     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  195-201     Citation Subset:  T    
Affiliation:
Department of Economy, University of Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Aspirin / economics*,  therapeutic use*
Double-Blind Method
Drug Costs
Humans
Myocardial Infarction / drug therapy*,  economics*
Platelet Aggregation Inhibitors / economics*,  therapeutic use*
Recurrence
Salicylates / economics*,  therapeutic use*
Spain
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 0/Salicylates; 322-79-2/triflusal; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Development of an economic model to assess the cost effectiveness of asthma management strategies.
Next Document:  Economic value of thrombolysis with adjunctive abciximab in patients with subacute peripheral arteri...